News & Updates

The COVID-19 pandemic had a negative impact on blood pressure (BP) control, as shown in a study using ambulatory BP monitoring (ABPM).

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.

Hyper- and hypothyroidism are causally associated with pre-eclampsia (PE), but PE does not causally influence thyroid dysfunctions, suggest the results of a Mendelian randomization (MR) study.